( resent a new approach to the treatment ...)Peer Reviewed Journal Article Indicates Repros' Proellex Exhibits,Potential for New Approach to the Treatment and Prevention of,Breast Cancer,Health

resent a new approach to the treatment of breast cancer in women that are refractory to either anti-estrogen or aromatase inhibitor therapy. In addition, the animal data discussed in the paper suggests that Proellex may have the potential to be developed for the prevention of breast cancer or in adjuvant therapy in combination with already approved anti-estrogen or aromatase inhibition based therapies.

Dr. Ronald Wiehle, VP of R&D at Repros, noted, "We are pleased with the performance of Proellex in clinical trials for the non-life-threatening conditions of endometriosis and uterine fibroids. In addition to Proellex providing real benefit to women suffering from these debilitating conditions, the drug has been remarkably well tolerated. We now have peer-reviewed evidence that Proellex may also be useful in the treatment of a significant life-threatening disease. Any potential for the prevention of breast cancer, if verified, would be especially good news for women taking Proellex for endometriosis and fibroids."

Joseph Podolski, President and CEO, added, "This report represents significant findings towards the potential for a new indication for Proellex. We are well down the road of preparing a complete dossier for NDA submission for Proellex in the treatment of uterine fibroids, which is expected around the end of 2008. Though not a trivial task, this new indication could be developed with a specific focus on efficacy questions while relying heavily on our existing and growing safety data base for Proellex." He further commented, "Our developmental portfolio of indications is very full at this time. We believe the opportunity to find a partner in the oncology arena for the breast cancer indication represents a great opportunity for the Company. We therefore plan to explore a potential collaborative relationship with one of the major oncology companies for the breast cancer indication."

About Repros Therapeutics Inc.

Repros is engaged
'"/>

Page: 1 2 3 4
Related medicine technology :

1. Medicures MEND-CABG Trial Results Published in Peer Reviewed Journal
2. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
5. New Study in Journal of Pediatrics Suggests Synagis (Palivizumab) May Reduce Subsequent Recurrent Wheezing in Preterm Infants
6. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
7. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
8. Research on New Treatment for Neglected Disease Published in The New England Journal of Medicine
9. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood